What Physicians must know about COPD:Clinical Pearls from the Updated GOLD 2025 guidelines

By Dr Shambo Samrat Samajdar; MBBS MD DM (Clinical Pharmacology); Fellowship in Respiratory and Critical Care (WBUHS); FIPS; Fellow of Diabetes India; PG Dip Endo & Diabetes (RCP); Diploma in Allergy Asthma Immunology (BV University)

Affiliation: Diabetes and Allergy-Asthma Therapeutics Specialty Clinic, Kolkata

This article distills the clinical pearls from the updated GOLD 2025 guidelines, focusing on actionable insights for healthcare professionals.

1. Expanding the Diagnostic Horizon

Key Updates:

Introduction of Pre-COPD and PRISm:
- Pre-COPD identifies individuals with symptoms or lung abnormalities, such as small airway disease or emphysema, even when spirometry is normal.
- PRISm (Preserved Ratio Impaired Spirometry) denotes a normal FEV1/FVC ratio but a reduced FEV1, highlighting early lung function decline.

Clinical Implications:

These categories facilitate early identification of at-risk patients, enabling interventions to slow progression before irreversible damage occurs.
Recognizing diverse pathophysiological profiles helps in tailoring treatments based on imaging findings, biomarkers, and clinical symptoms.

2. Advanced Diagnostic Tools

Imaging and Biomarkers:

High-Resolution CT Scans:
Detect structural changes, including emphysema and airway remodeling, in patients with normal spirometry.
Biomarkers:
- Blood eosinophil counts guide the use of anti-inflammatory therapies like inhaled corticosteroids (ICS) or biologics.

Enhanced Spirometry Standards:

Adoption of Lower Limit of Normal (LLN) and z-scores to reduce diagnostic misclassification in diverse populations.

Takeaway:

The integration of advanced tools with traditional spirometry offers a more holistic and precise diagnostic framework.

3. Proactive, Personalized Treatment Approaches

Updated Pharmacological Options:

Ensifentrine: A dual-mechanism drug combining bronchodilation and anti-inflammatory effects.
Dupilumab: Targets Type 2 inflammation, improving outcomes in COPD patients with eosinophilic profiles.

Patient-Centric Strategies:

Focus on treatable traits, such as systemic inflammation or airway hyperresponsiveness, ensures interventions are tailored to individual needs.

Clinical Focus:

The use of biomarker-driven decisions enables targeted therapy, reducing exacerbations and improving lung function while minimizing side effects.

4. Multimorbidity Management

Emphasis on Comorbid Conditions:

GOLD 2025 addresses common comorbidities, such as cardiovascular disease, diabetes, and osteoporosis, which exacerbate COPD symptoms and impact prognosis.
The “Treatable Traits” model promotes personalized care, tackling both pulmonary and systemic health risks.

Guidance for Clinicians:

Collaborative management involving pulmonologists, cardiologists, and other specialists improves patient outcomes.
Focus on pulmonary hypertension (PH) and its distinct treatment pathways highlights the complexity of COPD phenotypes.

5. Advanced Non-Pharmacological Interventions

Pulmonary Rehabilitation (PR):

PR improves exercise tolerance and quality of life while reducing exacerbations.
Virtual PR and Telehealth expand access to underserved populations, ensuring continuity of care.

Digital Health Tools:

Wearables and remote monitoring track symptoms, adherence, and progression, empowering both patients and providers.

Actionable Insight:

Non-pharmacological strategies remain cornerstones of comprehensive COPD care, complementing pharmacological treatments.

6. Climate Change and COPD

Environmental Risks:

Air pollution, wildfires, and temperature extremes exacerbate COPD symptoms and hospitalizations.
GOLD 2025 encourages patient education on air quality indices (AQI) and protective measures like air purifiers and masks.

Health Equity:

Addressing environmental and social disparities ensures vulnerable populations receive adequate support against climate-related risks.

Practical Application:

Integrating climate awareness into COPD management equips patients to navigate environmental challenges effectively.

7. Vaccination as Prevention

Updated Recommendations:

Annual influenza vaccination and pneumococcal vaccines (PCV20 or PPSV23) are essential for reducing infection-related exacerbations.
RSV Vaccines are newly recommended for adults aged 60+.

Preventive Focus:

Routine assessment of vaccination status during clinical visits helps maintain proactive disease management.

8. Clinical Integration: Key Takeaways

Recognize Early Stages: Utilize new diagnostic categories (Pre-COPD, PRISm) for proactive intervention.
Employ Advanced Tools: Integrate imaging and biomarkers for a comprehensive assessment.
Individualize Care: Tailor treatments to phenotypes and inflammatory profiles using pharmacological and non-pharmacological strategies.
Address Multimorbidities: Manage overlapping conditions to improve holistic health outcomes.
Adapt to Climate Change: Incorporate environmental risk reduction into patient care plans.
Vaccinate Preventively: Stay updated with evolving guidelines for infectious disease prevention.

Conclusion

The GOLD 2025 update represents a significant evolution in COPD care, emphasizing early detection, personalized management, and holistic strategies. These guidelines empower clinicians to redefine COPD as a preventable and manageable condition, improving long-term outcomes for millions worldwide. As we commemorate World COPD Day 2024, let’s commit to advancing COPD awareness and care through these transformative insights.

Reference:

1.https://goldcopd.org/wp-content/uploads/2024/11/Pocket-Guide-2025-v1.0-New-Format-15Nov2024_WMV.pdf